12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Company News  |  Other News

Novartis cancer news

India's Supreme Court upheld a 2009 ruling by India's Intellectual Property Appellate Board (IPAB) denying a patent for cancer drug Glivec imatinib from Novartis. In its decision, the Supreme Court said Novartis did not show that the beta crystalline form of imatinib mesylate has "enhanced efficacy" over the "known substance," which is the...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >